Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated August 11, 2025, reports a transaction in the company's own shares. The filing covers share repurchases executed on August 8, 2025, as part of an ongoing buyback program.
Key Financial Metrics
- Shares Purchased (August 8, 2025): 497,923 ordinary shares.
- Price Range: Lowest price paid was 1,389.50 GBp; highest price paid was 1,405.50 GBp.
- Average Price: Volume-weighted average price paid was 1,397.58 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Shares Held: 240,042,950 ordinary shares (post-transaction).
- Shares in Issue: 4,075,348,296 ordinary shares (excluding Treasury shares).
- Treasury Voting Rights: 5.89% of total voting rights.
Material Changes and Program Status
The purchase was executed pursuant to a non-discretionary agreement with Merrill Lynch International entered into on June 4, 2025. Since the inception of this specific agreement on June 4, 2025, the Company has purchased a total of 21,908,567 ordinary shares. The shares purchased on August 8 are held as Treasury shares.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, revenue outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q2 Results for 2025.
Investor Verification Checklist
- Verify the total number of shares purchased under the June 4, 2025 agreement (21,908,567) against the remaining authorization limit of the buyback program.
- Confirm the current percentage of voting rights held in treasury (5.89%) to assess potential dilution or concentration effects.
- Review the "Risk Factors" in the 2024 Form 20-F and 2025 Q2 results for context on the company's broader financial health and liquidity position.
- Monitor future 6-K filings to track the completion status of the non-discretionary buyback agreement.